Top Markets
Coin of the day
Mercury Biopharmaceutical Corporation Mercury Biopharmaceutical Corporation

Mercury Biopharmaceutical Corporation

6932
Rank in Stocks #23452
Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury... Founded in 2019 and headquartered in New Taipei City, Taiwan, Mercury Biopharmaceutical Corporation is dedicated to creating innovative pharmaceutical solutions for medical conditions currently lacking adequate treatment options. A cornerstone of their strategy is the proprietary StackDose platform, an advanced drug development system designed to formulate novel medication delivery methods. This platform facilitates precisely timed drug release, targeted absorption at specific locations within the body, and flexible dosage modifications. The primary objective of StackDose is to significantly boost the bioavailability of active pharmaceutical ingredients, leading to a reduction in required drug dosages and fewer adverse effects. Their development pipeline currently addresses a variety of ailments, such as erectile dysfunction, pulmonary hypertension, sleep disturbances, benign prostatic hyperplasia, angina, migraines, hypertension, and pain management.
Share Price
$0.17616661
Last synced: 2026-08-21
Market Cap
$73.48M
Change (1 day)
0.18%
Change (1 year)
-37.76%
Country
TW
Trade Mercury Biopharmaceutical Corporation (6932)

Category

P/B ratio for Mercury Biopharmaceutical Corporation (6932)
P/B ratio as of 2026 TTM: 0
According to Mercury Biopharmaceutical Corporation latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Mercury Biopharmaceutical Corporation from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors